LLY

911.36

-1.01%↓

UNH

597.64

+0.96%↑

NVO

117.53

+0.34%↑

JNJ

160.64

-0.12%↓

ABBV

194.4

-0.21%↓

LLY

911.36

-1.01%↓

UNH

597.64

+0.96%↑

NVO

117.53

+0.34%↑

JNJ

160.64

-0.12%↓

ABBV

194.4

-0.21%↓

LLY

911.36

-1.01%↓

UNH

597.64

+0.96%↑

NVO

117.53

+0.34%↑

JNJ

160.64

-0.12%↓

ABBV

194.4

-0.21%↓

LLY

911.36

-1.01%↓

UNH

597.64

+0.96%↑

NVO

117.53

+0.34%↑

JNJ

160.64

-0.12%↓

ABBV

194.4

-0.21%↓

LLY

911.36

-1.01%↓

UNH

597.64

+0.96%↑

NVO

117.53

+0.34%↑

JNJ

160.64

-0.12%↓

ABBV

194.4

-0.21%↓

Kodu・Aktsiate loetelu・Bristol-Myers Squibb Co.

Bristol-Myers Squibb Co.

Suletud

Sektor Tervishoid

52.44 -0.79

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

52.32

Max

53.4

Põhinäitajad
By Trading Economics
Sissetulek	14B 1.7B
Müük	300M 12B
P/E Sektori keskmine	14.05 113.916
Aktsiakasum	2.07
Kasumimarginaal	13.77
Töötajad	34,100
EBITDA	13B 4.4B

Soovitused
By TipRanks
Soovitused	Neutraalne
12 kuu keskmine prognoos	-4.7 downside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	31. okt 2024
Järgmine dividendimakse kuupäev	1. nov 2024

Turustatistika
By TradingEconomics
Turukapital	5.1B 109B
Eelmine avamishind	53.23
Eelmine sulgemishind	52.44

Uudiste sentiment

By Acuity

39%

61%

160 / 366 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Weak Bullish Evidence

52.41 / 53.4057 Toetus ja vastupanu

Bristol-Myers Squibb Co. Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

30. sept 2024, 13:06 UTC

Suurimad hinnamuutused turgudel

Prime Medicine Shares Rally on Partnership With Bristol Myers Squibb

26. juuli 2024, 14:08 UTC

Tulu

Trending: Bristol Myers Squibb 2Q Adjusted EPS Beat Expectations

26. juuli 2024, 11:54 UTC

Tulu

Bristol-Myers 2Q Adjusted EPS Tops Views on Strong Sales

25. apr 2024, 14:38 UTC

Tulu

Trending: Bristol Myers Squibb Cuts '24 EPS Outlook, Plans Job Cuts in Cost Saving Efforts

7. okt 2024, 14:16 UTC

Tulu

Omandamised, ülevõtmised, äriostud

Pfizer Stock Rises After It Gets an Activist. What Starboard's Track Record With Pharma Tells Us. -- Barrons.com

7. okt 2024, 13:45 UTC

Tulu

Omandamised, ülevõtmised, äriostud

Pfizer Stock Rises After It Gets an Activist. What Starboard's Track Record With Pharma Tells Us. -- Barrons.com

7. okt 2024, 11:54 UTC

Peamised uudised

Pfizer Gets an Activist. What Starboard's Track Record With Pharma Tells Us. -- Barrons.com

7. okt 2024, 09:30 UTC

Peamised uudised

Old Drug Repurposed for Schizophrenia Could Reap Alzheimer's Windfall -- Heard on the Street -- WSJ

27. sept 2024, 18:36 UTC

Tulu

These Stocks Are Moving the Most Today: Bristol Myers, Costco, EchoStar, Cassava, DJT, Wynn, HP Inc., Acadia Healthcare, and More -- Barrons.com

27. sept 2024, 09:15 UTC

Kuumad aktsiad

Stocks to Watch Friday: Bristol Myers Squibb, EchoStar, Costco -- WSJ

26. sept 2024, 23:20 UTC

Peamised uudised

First Novel Schizophrenia Treatment in Decades Gains FDA Approval -- Update

26. sept 2024, 22:56 UTC

Peamised uudised

First Novel Schizophrenia Treatment in Decades Gains FDA Approval -- WSJ

16. aug 2024, 11:30 UTC

Peamised uudised

The Feds Are 'Playing Nice' With Pharma, at Least for Now -- Heard on the Street -- WSJ

8. aug 2024, 10:30 UTC

Peamised uudised

Big Pharma Cuts R&D, Sending Shudders Through Industry -- Heard on the Street -- WSJ

29. juuli 2024, 10:30 UTC

Peamised uudised

Big Pharma Rallies and Moves Past Obesity -- Heard on the Street -- WSJ

26. juuli 2024, 14:51 UTC

Tulu

Bristol Myers Retakes Its 200-Day Line On Quarterly Beat, Surprise Immunology Win -- IBD

26. juuli 2024, 13:53 UTC

Tulu

Trending: Bristol Myers Squibb 2Q Adj EPS Beat Expectations

26. juuli 2024, 11:28 UTC

Tulu

Bristol Myers Stock Jumps. A Sales Jump for Eliquis Boosts Earnings. -- Barrons.com

26. juuli 2024, 11:14 UTC

Tulu

Bristol Myers Squibb Earnings Easily Beat On Cost Cuts; Stock Jumps -- IBD

26. juuli 2024, 11:06 UTC

Tulu

Bristol-Myers Squibb 2Q Adj Gross Margin 75.6% >BMY

26. juuli 2024, 11:06 UTC

Tulu

Bristol-Myers Squibb 2Q Gross Margin 73.2% >BMY

26. juuli 2024, 11:04 UTC

Tulu

Bristol-Myers Squibb Raises 2024 View To EPS 60c-EPS 90c Vs Prior Guidance 40c-70c >BMY

26. juuli 2024, 11:04 UTC

Tulu

Bristol-Myers Squibb Now Sees 2024 Total Rev Up Upper End of Low Single-Digit Range >BMY

26. juuli 2024, 10:59 UTC

Tulu

Bristol-Myers Squibb 2Q EPS 83c >BMY

26. juuli 2024, 10:59 UTC

Tulu

Bristol-Myers Squibb 2Q Net $1.68B >BMY

26. juuli 2024, 10:59 UTC

Tulu

Bristol-Myers Squibb 2Q Rev $12.2B >BMY

26. juuli 2024, 10:59 UTC

Tulu

Bristol-Myers Squibb 2Q Adj EPS $2.07 >BMY

19. juuni 2024, 05:30 UTC

Peamised uudised

Omandamised, ülevõtmised, äriostud

M&A Is Back. 4 Stocks That Could Be Targets. -- Barrons.com

28. mai 2024, 22:51 UTC

Market Talk

Omandamised, ülevõtmised, äriostud

Bristol Myers Squibb Adds to Neurodegenerative Treatment Investments -- Market Talk

25. apr 2024, 12:36 UTC

Tulu

Bristol Myers Cuts Full-Year Earnings Forecast, Launches Cost Cuts -- Barrons.com

Võrdlus sarnastega

Hinnamuutus

Bristol-Myers Squibb Co. Prognoos

Hinnasiht

By TipRanks

-4.7% langus

12 kuu keskmine prognoos

Keskmine 50.32 USD -4.7%

Kõrge 60 USD

Madal 33.1 USD

Põhineb 16 Wall Streeti analüütiku instrumendi Bristol-Myers Squibb Co. 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Neutraalne

16 ratings

Osta

Hoia

Müü

Põhineb 16 analüütiku instrumendi Bristol-Myers Squibb Co. aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

52.41 / 53.4057Toetus ja vastupanu

Bullish events outweigh bearish events.

All events are bullish.

Recent bullish events outweigh bearish events.

Sentiment

By Acuity

160 / 366 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Bristol-Myers Squibb Co.

Bristol-Myers Squibb Company is a biopharmaceutical company. The Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. It offers products for a range of therapeutic classes, which include oncology, immunology, cardiovascular and fibrosis. Its pharmaceutical products include chemically-synthesized or small molecule drugs and products produced from biological processes, called biologics. Small molecule drugs are administered orally in the form of a pill or tablet. Biologics are administered to patients through injections or by infusion. Its products include Revlimid, Eliquis, Opdivo, Orencia, Pomalyst/Imnovid, Sprycel, Yervoy, Abraxane, Empliciti, Reblozyl, Inrebic, Onureg, Zeposia, Vidaza, Baraclude and Breyanzi. Its products are sold to wholesalers, distributors, pharmacies, retailers, hospitals, clinics and government agencies.